A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Background Inhibition of the programmed cell death protein 1 (PD‐1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid‐der...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer Ročník 126; číslo 20; s. 4485 - 4497
Hlavní autori:	Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 15.10.2020 John Wiley and Sons Inc
Predmet:	Alanine Alanine transaminase Anemia Apoptosis Bladder cancer Bruton's tyrosine kinase Cancer CD8 antigen Cell activation Cell death Correlation analysis Immune system Immunotherapy Kinases Lymphocytes Lymphocytes T Metastases Metastasis Monoclonal antibodies Monocytes Oncology Original Patients Pembrolizumab Platinum programmed cell death receptor 1 protein kinase inhibitor Protein-tyrosine kinase Solid tumors Suppressor cells Survival Targeted cancer therapy Tumors Tyrosine Urinary tract urologic neoplasms Urothelial cancer Urothelial carcinoma protein kinase inhibitor programmed cell death receptor 1 immunotherapy urologic neoplasms
ISSN:	0008-543X, 1097-0142, 1097-0142
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!